Analysed SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) News Sources
SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out?
01-07-2026
stocktwits.com
SELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial Data
01-07-2026
yahoo.com
SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success
02-07-2026
stocktwits.com
SLS Stock Notches 3-Week Winning Run: MassMutual Opens Tiny Stake Ahead Of Key AML Readout
06-07-2026
stocktwits.com
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick
07-07-2026
stocktwits.com
SLS Stock Logs 2-Day Losing Streak: Mixed Institutional Bets Emerge Ahead Of Key AML Trial Update
08-07-2026
stocktwits.com
SLS Stock In The Spotlight As CEO Pushes Back On Regal Trial Criticism – ‘Let’s Separate The Noise From The Data’
08-07-2026
stocktwits.com
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY
09-07-2026
stocktwits.com
What is the current price of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The current price of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is $12.76.
SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) absolute price change since previous trading day?
The absolute price change of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) since the previous trading day is $-0.75.
SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) percentage price change since previous trading day?
The percentage price change of SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) since the previous trading day is -5.5514%.
What is the most recent average sentiment score for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The most recent average sentiment score for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is 56 out of 100.
What is the most recent average sentiment for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)?
The most recent sentiment for SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ) is .
SEC-8K** Filing Available For SELLAS LIFE SCIENCES GROUP I (SLS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.